Machado Joseph Disease (Spinocerebellar Ataxia Type 3) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
| Machado-Joseph Disease (Spinocerebellar Ataxia Type 3) | |
|---|---|
| Cerebellar and brainstem atrophy on MRI | |
| Also Known As | SCA3, MJD, Azorean Disease, Spinocerebellar Ataxia Type III |
| ICD-10 | G11.2 |
| OMIM | 109150 |
| Inheritance | Autosomal dominant |
| Gene | ATXN3 (Ataxin-3), chromosome 14q32.1 |
| Mutation | CAG trinucleotide repeat expansion (normal: 12–43; pathogenic: ≥52) |
| Onset | Typically 20–50 years (range: childhood to 70s) |
| Key Features | Progressive cerebellar ataxia, pyramidal signs, external ophthalmoplegia, peripheral neuropathy |
| Prevalence | Most common SCA worldwide (~20% of all SCAs; up to 50% in some populations) |
Machado-Joseph disease (MJD), also designated Spinocerebellar Ataxia type 3 (SCA3), is the most common autosomal dominant [cerebellar ataxia] worldwide, accounting for
approximately 20% of all spinocerebellar ataxias globally and up to 50% or more in Portuguese, Brazilian, German, Japanese, and Taiwanese populations.[1] The disease is caused by an unstable CAG trinucleotide repeat expansion in the [ATXN3 gene] on
chromosome 14q32.1, which encodes the deubiquitinating enzyme ataxin-3.[2]
MJD was first described independently in families of Azorean-Portuguese descent in the 1970s: the Machado family (reported by Nakano et al., 1972), the Thomas family (Woods and Schaumburg, 1972), and the Joseph family (Rosenberg et al., 1976). The condition was later unified as a single disease entity when the common genetic basis was identified in 1994. The name "Machado-Joseph disease" persists alongside the SCA3 designation in recognition of the founding families.[3]
MJD/SCA3 is characterized by remarkable clinical heterogeneity, with presentations ranging from early-onset dystonia-predominant forms to late-onset peripheral neuropathy variants. This variability is driven primarily by CAG repeat length, with larger expansions correlating with earlier onset and more severe disease, a phenomenon common to [polyglutamine expansion disorders].[2]
MJD/SCA3 is the most prevalent autosomal dominant ataxia in most populations studied. It constitutes approximately 20% of dominant ataxias in most US studies, approaching 50% or more in series from Portugal, the Azores, Brazil, Germany, Japan, and Taiwan.[1] The highest prevalence occurs on Flores Island in the Azores, where it reaches approximately 1 in 239 individuals, reflecting a founder effect from the Portuguese colonization era.
Global prevalence estimates for all SCAs combined are approximately 1–5 per 100,000, placing SCA3 prevalence at roughly 0.2–2.5 per 100,000 depending on the population. The disease affects males and females equally, with age of onset typically between 20 and 50 years, though the full range extends from childhood to the eighth decade.[4]
The causative mutation is an expanded CAG repeat in exon 10 of the ATXN3 gene. Normal alleles contain 12–43 CAG repeats, while pathogenic alleles contain 52–86 or more repeats. Alleles with 44–51 repeats represent a zone of reduced penetrance where disease may or may not manifest. The expanded polyglutamine tract in the resulting ataxin-3 protein confers toxic gain-of-function properties, including propensity for aggregation and formation of intranuclear inclusions.[2]
MJD/SCA3 demonstrates [genetic anticipation] — the tendency for CAG repeats to expand across generations, leading to earlier onset and more severe disease in successive generations. This is particularly pronounced in paternal transmission, where spermatogenesis-associated repeat instability can produce large intergenerational expansions. The inverse correlation between CAG repeat length and age of onset accounts for approximately 50–75% of the variance in onset age.[5]
Additional factors modifying disease presentation include:
Normal ataxin-3 is a 42-kDa deubiquitinating enzyme (DUB) with an N-terminal Josephin domain that cleaves ubiquitin chains from substrate proteins, playing roles in ubiquitin-proteasome system-mediated protein degradation, [aggresome] formation, [transcriptional regulation], and cytoskeletal dynamics.[7]
The expanded polyglutamine tract causes ataxin-3 to:
Despite ubiquitous expression of ataxin-3, neurodegeneration in SCA3 preferentially affects specific brain regions:
Three classic clinical subtypes of MJD are recognized, though overlap is common:
Type I (Dystonic-Rigid): Early onset (typically 10–30 years), characterized by prominent pyramidal signs (spasticity, hyperreflexia), dystonia, and rigidity with relatively less ataxia. Often associated with larger CAG expansions. Accounts for approximately 13% of patients.[1]
Type II (Ataxic): The most common presentation (57% of patients), with intermediate onset (20–50 years). Predominant cerebellar ataxia with progressive gait and limb ataxia, dysarthria, nystagmus, and progressive external ophthalmoplegia (PEO). May also exhibit pyramidal signs and spasticity.[1]
Type III (Peripheral Neuropathy): Later onset (typically 40–70 years), with prominent peripheral neuropathy causing distal muscle wasting, hyporeflexia, and sensory loss, in addition to cerebellar ataxia. Associated with smaller CAG repeat expansions. Accounts for approximately 30% of patients.[4]
Common clinical features across subtypes include:
The diagnosis is confirmed by molecular genetic testing demonstrating a heterozygous CAG trinucleotide repeat expansion of ≥52 repeats in ATXN3. Genetic testing should be considered in individuals with progressive cerebellar ataxia and a dominant family history, particularly when accompanied by external ophthalmoplegia, pyramidal signs, or peripheral neuropathy.[4]
MRI reveals characteristic patterns of brain atrophy:
Emerging [biomarkers] include:
No disease-modifying treatment is currently available. Management is symptomatic:
Several promising therapeutic approaches are in preclinical and early clinical development:
Antisense Oligonucleotides (ASOs): ATXN3-targeting ASOs have achieved sustained reduction of polyglutamine-expanded ataxin-3 for up to 8 weeks after treatment in mouse models, preventing oligomeric and nuclear accumulation and rescuing motor impairment with longitudinal therapy.[11]
Gene Editing: CRISPR/Cas-mediated correction of the ATXN3 CAG expansion in SCA3 patient-derived iPSCs has rescued neurodegenerative phenotypes, providing proof-of-concept for cell-based therapeutic approaches.[12]
RNA Interference: Self-assembling siRNA constructs directed against mutant ATXN3 have shown efficacy in reducing neuroinflammation and ataxin-3 levels in SCA3 mouse models, published in Brain in 2025.[13]
Autophagy Inducers: Given evidence of deficient autophagy biomarkers in SCA3, drugs that enhance autophagic clearance of mutant ataxin-3 represent an active area of investigation, including rapamycin analogs and lithium.[8]
SCA3 is progressive and currently incurable. Average disease duration from onset to death is approximately 20–25 years, though this varies substantially. Death typically results from complications of dysphagia (aspiration pneumonia), falls, or general immobility. Quality of life is significantly impacted, with loss of independent ambulation occurring on average 10–15 years after onset.[1]
The study of Machado Joseph Disease (Spinocerebellar Ataxia Type 3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.